Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;43(11):6593-6594.
doi: 10.1007/s10072-022-06239-w. Epub 2022 Jun 29.

Teriflunomide-induced Raynaud's phenomenon: a serious adverse event, previously unreported

Javier Riancho  1   2   3 , Manuel Delgado-Alvarado  4   5 , Leyre Riancho-Zarrabeitia  6
Affiliations

Teriflunomide-induced Raynaud's phenomenon: a serious adverse event, previously unreported

Javier Riancho et al. Neurol Sci. 2022 Nov.
No abstract available

Keywords: Multiple sclerosis; Raynaud; Teriflunomide.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293–1303 - DOI - PubMed
    1. Landete L, Perez-Miralles F, Garcia S, Belenguer A, Gascon F, Dominguez JA et al (2021) Treatment of multiple sclerosis with teriflunomide. Multicenter study of real clinical practice in the Valencian Community-Spain. Front Neurol 12:727586 - DOI - PubMed - PMC
    1. Herrick AL (2021) Raynaud’s phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 33(6):453–462 - DOI - PubMed
    1. Bouquet E, Urbanski G, Lavigne C, Laine-Cessac P (2017) Unexpected drug-induced Raynaud phenomenon: analysis from the French national pharmacovigilance database. Therapie 72(5):547–554 - DOI - PubMed

LinkOut - more resources